View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 7, 2021

Precirix begins subject dosing in Phase I/II cancer therapy trial

The trial will analyse CAM-H2’s safety, tumour uptake, retention, and antitumour activity in HER2-positive cancer patients.

Precirix has dosed the first subjects in the Phase I/II clinical trial of its lead therapeutic asset, CAM-H2, to treat human epidermal growth factor receptor 2 (HER2)-positive metastatic cancer.

CAM-H2 includes a single-domain antibody that acts on HER2, covalently linked to iodine-131.

The company noted that single-domain antibodies are well fitted for targeted radiation delivery to tumours based on the size, specificity and pharmacokinetic properties.

The trial will assess the safety, tumour uptake, tumour retention as well as initial signs of antitumour activity of CAM-H2 in patients with HER2-positive metastatic breast and gastric/gastro-oesophageal cancer.

These subjects should have relapsed or are refractory to existing anti-HER2 treatments.

The continuous trial will have two segments.

Phase I dose-escalation trial will identify the recommended dose of the treatment for Phase II trial in 3+3 dose-ascending groups of subjects while Phase II will be a dose-expansion trial.

Precirix noted that the Phase I/II trial will also enrol brain metastases patients and have a total of nearly 70 subjects.

Precirix NV CEO Ruth Devenyns said: “We are very excited to have dosed the first patients in this clinical study, the result of years of thorough scientific research, collaboration, and operational excellence of our entire team and partners.

“We look forward to recruiting additional patients and generating efficacy data to confirm the strong results from our preclinical and first-in-human studies, with the goal of bringing new treatment options to cancer patients.”

HER2 is a validated treatment target and several agent, which act on HER2 are approved.

However, these therapies are not effective against metastatic disease and brain metastases have few therapy options.

No HER2 targeting radiopharmaceuticals are currently authorised for usage and CAM-H2 is the lead asset being developed which uses a single-domain antibody to offer targeted radiation to cancer.

This product also offers a novel mechanism of action in the existing HER2 therapy landscape to address key unmet medical needs, including brain metastases and reduced HER2 expression.

Precirix has a wide pipeline with one asset in a Phase I/II trial while two others are currently in the preclinical stage of development.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy